Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A single blood draw to detect five cancers before symptoms appear?

NCT ID NCT06790355

Diagnosis Sponsor: Shanghai Weihe Medical Laboratory Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests a blood-based test designed to detect multiple cancers early in people aged 40 to 74 who have no cancer symptoms. The study will enroll about 2,500 participants and will check how well the test identifies lung, colorectal, liver, gastric, and esophageal cancers. Researchers will also measure how often a positive test leads to a confirmed diagnosis and how quickly people get a clear answer after a positive result.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood-based multi-cancer early detection test
What this could lead to
If the test works, it could lead to a simple blood draw that helps catch several cancers early, when treatment is more likely to succeed.
What could go wrong
This is an early feasibility study, so the test may not be accurate enough or may cause unnecessary follow-up procedures. The results will need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2,527 people

The number who actually took part.

Started

Mar 2025

Finished

Aug 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 74 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 40-74 years old * Able to provide a written informed consent and willing to comply with all parts of the protocol procedures Exclusion Criteria: * With cancer-associated clinical symptoms or suspected of cancer within 30 days prior to screen * Have definite contraindications of cancer screening examination and diagnostic procedures * Unable to comply with the protocol procedures * Personal history of cancer, diagnosed within the 3 years prior to expected enrollment date * Have received or are undergoing curative cancer treatment within three years prior to recruitment. Adjuvant endocrinotherapy for cancer is not an exclusion criterion. * Recipients of anti-tumor therapy within 30 days prior to screen * Pregnancy or lactating women * Recipients of organ transplant or prior bone marrow transplant or stem cell transplant * Recipients of blood transfusion within 7 days prior to screen * With autoimmune diseases * Have an acute infection or inflammation or uncontrolled chronic infection within 14 days prior to blood draw * Unsuitable for this trial determined by the researchers (eg. hemorrhagic diseases)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm esophageal cancer Esophageal Neoplasms gastric cancer liver cancer Liver Neoplasms lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer Esophageal cancer Grastic cancer Liver cancer Lung cancer

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350014, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450008, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, 210009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.